跳到主要导航 跳到搜索 跳到主要内容

Impact of potential modifications to Alzheimer’s disease clinical trials in response to disruption by COVID-19: a simulation study

  • Lon S. Schneider*
  • , Yuqi Qiu
  • , Ronald G. Thomas
  • , Carol Evans
  • , Diane M. Jacobs
  • , Shelia Jin
  • , Jeffrey A. Kaye
  • , Andrea Z. LaCroix
  • , Karen Messer
  • , David P. Salmon
  • , Mary Sano
  • , Kimberly Schafer
  • , Howard H. Feldman
  • *此作品的通讯作者
  • University of Southern California
  • University of California at San Diego
  • Oregon Health and Science University
  • Icahn School of Medicine at Mount Sinai

科研成果: 期刊稿件 › 文章 › 同行评审

摘要

Background: The COVID-19 pandemic disrupted Alzheimer disease randomized clinical trials (RCTs), forcing investigators to make changes in the conduct of such trials while endeavoring to maintain their validity. Changing ongoing RCTs carries risks for biases and threats to validity. To understand the impact of exigent modifications due to COVID-19, we examined several scenarios in symptomatic and disease modification trials that could be made. Methods: We identified both symptomatic and disease modification Alzheimer disease RCTs as exemplars of those that would be affected by the pandemic and considered the types of changes that sponsors could make to each. We modeled three scenarios for each of the types of trials using existing datasets, adjusting enrollment, follow-ups, and dropouts to examine the potential effects COVID-19-related changes. Simulations were performed that accounted for completion and dropout patterns using linear mixed effects models, modeling time as continuous and categorical. The statistical power of the scenarios was determined. Results: Truncating both symptomatic and disease modification trials led to underpowered trials. By contrast, adapting the trials by extending the treatment period, temporarily stopping treatment, delaying outcomes assessments, and performing remote assessment allowed for increased statistical power nearly to the level originally planned. Discussion: These analyses support the idea that disrupted trials under common scenarios are better continued and extended even in the face of dropouts, treatment disruptions, missing outcomes, and other exigencies and that adaptations can be made that maintain the trials’ validity. We suggest some adaptive methods to do this noting that some changes become under-powered to detect the original effect sizes and expected outcomes. These analyses provide insight to better plan trials that are resilient to unexpected changes to the medical, social, and political milieu.

源语言英语
期刊论文编号201
期刊Alzheimer's Research and Therapy
卷13
期1
DOI
出版状态已出版 - 12月 2021
已对外发布是

学术指纹

探究 'Impact of potential modifications to Alzheimer’s disease clinical trials in response to disruption by COVID-19: a simulation study' 的科研主题。它们共同构成独一无二的学术指纹。

引用此